Nascent Biotech CEO Sean Carrick tells Proactive the group is approaching its final cohort of its Phase I clinical study to treat brain cancer with its lead product, Pritumumab, a natural human antibody. Carrick says Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer.
Nascent Biotech approaching final cohort for its Phase I clinical study to treat brain cancer
